SERB Pays $800m For Boston Scientific Specialty Pharma Business
Device Maker Acquired The Drugs In $4.2bn BTG Buy Last Year
Executive Summary
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.